FDA extends review time for Biogen’s ALS treatment candidate

Shares of Biogen Inc. BIIB, -1.97% gained 1.4% in premarket trading on Monday after telling investors that the Food and Drug Administration extended the review period for its experimental treatment for amyotrophic lateral sclerosis (ALS) by three months. The new decision date is April 25. Biogen’s stock is up 10.3% this year, while the S&P 500 SPX, -2.37% is down 24.8%.